20 innovative pharmaceutical concept stocks reported good performance in the first half of the year.

Currently, it is the peak period of performance forecast disclosure. According to Securities Times Databao statistics, as of the close of July 15th, there are 20 innovative drug concept stocks that are expected to see year-on-year growth in net profit for the first half of 2026. Jilin Aodong is expected to have the highest profit, with the company expecting a net profit of 19.22 billion to 21.79 billion yuan in the first half of 2026, a year-on-year increase of 50% to 70%. The main reason for the significant increase in performance is the increase in investment income. Other companies expected to have high profits include Tianyuanli, Haisike, Huahai Pharmaceutical, Kanglong Huacheng, and Zhaoyan New Drug.